1-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪 |
| 时间：2023-07-15 来源：化工号 作者：C38H35N5O6S2 |
化合物KN-621-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪5-异喹啉磺酸 4-[(2S)-2-[(5-异喹啉磺酰基)甲氨基]-3-氧代-3-(4-苯基-1-哌嗪基)丙基]苯酯
| 中文名 | 1-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪
| | 英文名 | 4-[(2s)-2-[(5-Isoquinolinylsulfonyl)Methylamino]-3-Oxo-3-(4-Phenyl-1-Piperazinyl)Propyl] Phenyl Isoquinolinesulfonic Acid Ester
| | 别名 | 化合物KN-62
1-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪
5-异喹啉磺酸 4-[(2S)-2-[(5-异喹啉磺酰基)甲氨基]-3-氧代-3-(4-苯基-1-哌嗪基)丙基]苯酯
| | 英文别名 | KN-62
CS-756
1-(N,O-BIS-(5-ISOQUINOLINESULFONYL)-*N-M ETHYL-L-TYR
1-[N,O-Bis-(5-Isoquinolinesulfonyl)-N-Methyl-L-Tyrosyl]-4-Phenylpiperazine
(S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate
4-{2-[(isoquinolin-5-ylsulfonyl)(methyl)amino]-3-oxo-3-(4-phenylpiperazin-1-yl)propyl}phenyl isoquinoline-5-sulfonate
4-((2S)-2-((5-isoquinolinylsulfonyl)methylamino)-3-oxo-3-(4-phenyl-1-piperazinyl)propyl)phenylisoquinolinesulfonicacid
4-((2s)-2-((5-Isoquinolinylsulfonyl)Methylamino)-3-Oxo-3-(4-Phenyl-1-Piperazinyl)Propyl)Phenylisoquinolinesulfonicacid
4-[(2S)-2-[(isoquinolin-5-ylsulfonyl)(methyl)amino]-3-oxo-3-(4-phenylpiperazin-1-yl)propyl]phenyl isoquinoline-5-sulfonate
4-[(2s)-2-[(5-Isoquinolinylsulfonyl)Methylamino]-3-Oxo-3-(4-Phenyl-1-Piperazinyl)Propyl] Phenyl Isoquinolinesulfonic Acid Ester
(s)-5-isoquinolinesulfonic acid 4-[2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl)propyl]phenyl ester
(S)-5-Isoquinolinesulfonic Acid 4-(2-[(5-Isoquinolinylsulfonyl)Methylamino]- 3-Oxo-3-[4-Phenyl-1-Piperazinyl]Propyl)Phenyl Ester
5-Isoquinolinesulfonic acid, 4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1-piperazinyl)propyl]phenyl ester
1-(N,O-Bis-[5-isoquinolinesulfonyl]-N-methyl-L-tyrosyl)-4-phenylpiperazine, (S)-5-Isoquinolinesulfonic Acid 4-(2-[(5-Isoquinolinylsulfonyl)methylamino]- 3-oxo-3-[4-phenyl-1-piperazinyl]propyl)phenyl Ester,
| | CAS | 127191-97-3
| | 化学式 | C38H35N5O6S2
| | 分子量 | 721.84 | | InChI | InChI=1/C38H35N5O6S2/c1-41(50(45,46)36-11-5-7-29-26-39-19-17-33(29)36)35(38(44)43-23-21-42(22-24-43)31-9-3-2-4-10-31)25-28-13-15-32(16-14-28)49-51(47,48)37-12-6-8-30-27-40-20-18-34(30)37/h2-20,26-27,35H,21-25H2,1H3/t35-/m0/s1 | | 密度 | 1.388 | | 熔点 | 92-94°C | | 沸点 | 964.7±75.0 °C(Predicted) | | 闪点 | 537.2°C | | 蒸汽压 | 0mmHg at 25°C | | 溶解度 | 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.93mg/mL | | 折射率 | 1.685 | | 酸度系数 | 4.07±0.13(Predicted) | | 存储条件 | -20°C | | 外观 | solid | | 颜色 | white | | 物化性质 | 溶解度：45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.93 mg/mL
储存条件：?20℃
WGK Germany：3 | | 体外研究 | KN-62 is a selective antagonist of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII). KN-62 potently antagonizes ATP-stimulated Ba 2+ influx into fura-2 loaded human lymphocytes with an IC 50 of 12.7±1.5 nM (n=3) and complete inhibition of the flux at a concentration of 500 nM. Similarly, KN-62 inhibits ATP-stimulated ethidium + uptake, measured by time resolved flow cytometry, with an IC 50 of 13.1±2.6 nM (n=4) and complete inhibition of the flux at 500 nM. KN-62 is found to be a potent antagonist in a functional assay, inhibition of ATP-induced K + efflux in HEK293 cells expressing recombinant human P2X 7 receptors. In human leukemic B lymphocytes, KN-62 reduces the rate of permeability increase to larger permeant cations, like ethidium, induced by Bz-ATP with an IC 50 of 13.1 nM. KN-62 at a concentration of 3 µM has no effect on ATP-induced ethidium influx through the rat P2X 7 receptor, while the IC 50 at the human P2X 7 receptor is 0.1 µM. KN-62 has considerable selectivity for P2X 7 receptors within the P2 family. | | 体内研究 | The antidepressant-like behavior of ZnCl 2 (10 mg/kg, p.o.) (p<0.01) is prevented by CAMKII inhibitor KN-62 (1 μg/site, i.c.v.). The two-way ANOVA reveals a significantly main effect of KN-62 treatment [F(1,28)=27.47, p<0.01], no main effect of ZnCl 2 treatment [F(1,28)=0.84, p>0.05] and a significant effect of KN-62×ZnCl 2 treatment interaction [F(1,28)=22.57, p<0.01] to immobility time. As revealed by the post-hoc analysis, the anti-immobility effect of ZnCl 2 is completely prevented by treatment of animals with KN-62. No effect in locomotor activity in the open-field test is observed: (KN-62 treatment [F(1,24)=1.97, p>0.05], ZnCl 2 treatment [F(1,24)=3.99, p>0.05] and KN-62×ZnCl 2 treatment interaction [F(1,24)=0.61, p>0.05]). | | 安全术语 | 24/25 - 避免与皮肤和眼睛接触。
| | WGK Germany | 3 | | 海关编号 | 29339980 |
|
|
|
|
